News 20.02.2020 Zurich-Schlieren, Switzerland, February 20, 2020. Molecular Partners AG (SIX: MOLN), a clinicalstage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced the nomination of three new board members, proposed for election at the 2020 Annual General Meeting on April 29, 2020. Nominees are as follows: • Sandip...
Internal events
Event date: 20.02.2020
In this event, representatives from Johnson & Johnson will provide an overview of goals and missions, highlighting how Johnson & Johnson Innovation interacts with the entrepreneurial community through their network of healthcare incubators JLABS, the Venture Fund JJDC, the Innovation Centers and Janssen Business & Development.
Time: 20th February, 17:00 –...
News 06.02.2020 Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA and EMA filings accepted and under...
News 30.01.2020 Schlieren (Zurich), Switzerland, January 30, 2020 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone, Vitoss® BA2X (Stryker Corp.) and Novabone Putty® (Novabone Products, LLC) in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study...
Internal events
Event date: 25.02.2020
WHEN: 25 February 2020 09:00 - 12:00
WHERE: Bio-Technopark Auditorium, Wagistrasse 25, Schlieren-Zurich
In preparation for the second Redefining Early Stage Investments (RESI) conference to be held in Europe, Life Science Nation and Venture Valuation are offering Tech Hubs around Europe a Bootcamp addressing key topics for early-stage life science companies.
Program and...